What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial
HyBryte’s setback leaves Soligenix with cash, orphan assets, and a harder question. Can SGX945 reset the rare disease story?
Pharma & Biotech
Pharma & Biotech
How Soligenix is trying to turn tolerability and treatment logistics into a differentiated regulatory and commercial story
Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.